People News from the 10/17/06 News Brief

MANUFACTURERS The International Federation of Pharmaceutical Manufacturers and Associations has elected Schering-Plough’s Fred Hassan as its new president. The group also elected Alessandro Banchi, chairman of Boehringer Ingelheim and Haruo Naito, CEO of Eisai as vice presidents. The new leadership’s term extends from now until fall 2008. Pfizer promoted Edmund Harrigan to SVP of worldwide licensing and business development. Enzo Biochem named Gary Cupit to the newly created position of President of Enzo Therapeutics. Cupit, a senior executive with 20 years experience in the pharmaceutical industry who once headed global search and evaluation in business development and licensing for Novartis, was most recently CEO of Sapphire Therapeutics, a private company developing small molecule compounds to treat cancer and metabolic diseases. AGENCIES Fission Communications hired Florencia Schapiro as clinical director. Schapiro comes to Fission from Jobson Medical Information in Princeton, NJ, where she worked as a scientific coordinator. She previously held a post-doctoral appointment at Weill Medical College of Cornell University. Fission has also promoted Peter Mirabile to senior director, medical and scientific affairs. Mirabile served as Fission’s medical director for the last two years. SUPPLIERS Mark Gulledge has joined Scienta Healthcare Education as a program manager supervising CME initiatives in hemophilia. Gulledge joins Scienta after seven-and-a-half years with Thomson American Health Consultants, now AHC Media LLC, in Atlanta, last serving as director of electronic services for the sponsored education department.
You must be a registered member of MMM to post a comment.

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.